Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination.
Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination.
复制标题
DOI:
10.3390/vaccines9090974
复制
发表时间:
2021-08-31
期刊:
影响因子:
7.8
通讯作者:
Leong KP
中科院分区:
文献类型:
--
作者:
Lim XR;Leung BP;Ng CYL;Tan JWL;Chan GYL;Loh CM;Tan GLX;Goh VHH;Wong LT;Chua CR;Tan SC;Lee SSM;Howe HS;Thong BYH;Leong KP
Anaphylactic reactions were observed after Singapore’s national coronavirus disease 2019 (COVID-19) vaccination programme started in December 2020. We report the clinical and laboratory features of three patients in our institution who developed anaphylactic reactions after receiving the Pifzer BNT162b2 vaccine. IgM and IgG antibodies, but not IgE antibodies to the Pfizer BNT162b2 vaccine, were detected in all subjects. Similarly, mild to high elevated levels of anti-polyethylene glycol (PEG) IgG (1035–19709 U/mL, vs. vaccine-naive < 265 U/mL, vaccine-tolerant < 785 U/mL) and IgM (1682–5310 U/mL, vs. vaccine-naive < 1011 U/mL, vaccine-tolerant < 1007 U/mL) were detected in two out of three patients via commercial ELISA. High levels of serum anaphylatoxin C3a (79.0 ± 6.3 μg/mL, mean ± SD, vs. normal < 10 μg/mL) were observed in all three patients during the acute phase of the reaction, while tryptase levels, a marker of mast cell activation, were not elevated. Finally, one patient with the highest levels of anti-PEG IgG, IgM, and anti-Pfizer BNT162b2 IgG and IgM exhibited an enhanced Th2 cytokine serum profile during an acute reaction, with high levels of IL-4 (45.7 pg/mL, vs. vaccine-naive/tolerant < 2.30 pg/mL), IL-33 (86.4 pg/mL, vs. vaccine-naive/tolerant < 5.51 pg/mL) and IL-10 (22.9 pg/mL, vs. vaccine-naive/tolerant < 12.49 pg/mL) diminishing over time following corticosteroid treatment. Taken together, we propose these cases of anaphylaxis described are driven by a complement activation-related pseudoallergy (CAPRA), rather than classical IgE-mediated mechanisms.
登录
查看更多内容
DOI:
10.1016/j.jaci.2021.04.002
发表时间:
2021-06
期刊:
The Journal of allergy and clinical immunology
影响因子:
--
作者:
Risma KA;Edwards KM;Hummell DS;Little FF;Norton AE;Stallings A;Wood RA;Milner JD
通讯作者:
Milner JD
影响因子:
14.2
作者:
Stone, Shelley F.;Cotterell, Claire;Brown, Simon G. A.
通讯作者:
Brown, Simon G. A.
影响因子:
33.9
作者:
Shimabukuro, Tom
通讯作者:
Shimabukuro, Tom
DOI:
10.1016/j.jaci.2016.02.015
发表时间:
2016-06
期刊:
The Journal of allergy and clinical immunology
影响因子:
--
作者:
Finkelman FD;Khodoun MV;Strait R
通讯作者:
Strait R
DOI:
10.1016/j.jaip.2020.12.047
发表时间:
2021-04
期刊:
The journal of allergy and clinical immunology. In practice
影响因子:
--
作者:
Banerji A;Wickner PG;Saff R;Stone CA Jr;Robinson LB;Long AA;Wolfson AR;Williams P;Khan DA;Phillips E;Blumenthal KG
通讯作者:
Blumenthal KG